Hospital
Roosevelt County Special Hospital District
Roosevelt County Special Hospital District was paid $13.24M by Medicaid between Jan 2018 and Dec 2024, across 201 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoROOSEVELT COUNTY SPECIAL HOSPITAL DISTRICT
PORTALES, NM 88130
PORTALES, NM 88130
33aNPI1073517058assigned 06/08/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.24M
24GClaims326,531
24DCodes billed201
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#14 of 24
Median peer was paid$20.13M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 54,033 | $2.04M | |
| 2019 | 47,656 | $1.96M | |
| 2020 | 27,958 | $1.04M | |
| 2021 | 31,560 | $1.18M | |
| 2022 | 46,914 | $1.80M | |
| 2023 | 62,314 | $2.60M | |
| 2024incomplete | 56,096 | $2.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 11,792 | 10,821 | $2.41M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.0% | 7,720 | 7,362 | $1.19M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.9% | 2,195 | 2,123 | $777K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.6% | 1,949 | 1,826 | $738K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.4% | 2,663 | 2,440 | $714K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.2% | 9,399 | 2,394 | $556K |
| 80053 | Comprehensive metabolic panel | 3.1% | 26,175 | 22,617 | $411K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.8% | 5,009 | 1,185 | $367K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.7% | 7,264 | 6,249 | $354K |
| G0378 | Hospital observation service, per hour | 2.7% | 998 | 799 | $352K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.5% | 3,347 | 2,598 | $331K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 1,941 | 1,764 | $320K |
189 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 5,479 | $284K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 4,451 | $214K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 4,157 | $181K |
| 76000 | 1.3% | 1,388 | $177K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 9,590 | $170K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 3,106 | $161K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 1,043 | $156K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 555 | $140K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 1,402 | $137K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 3,743 | $133K |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,327 | $126K |
| 85027 | <1% | 16,106 | $107K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,164 | $102K |
| 80061 | Lipid panel | <1% | 5,782 | $93K |
| 83880 | <1% | 4,020 | $90K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 748 | $84K |
| 84484 | <1% | 5,013 | $76K | |
| 97597 | <1% | 959 | $70K | |
| 87400 | <1% | 2,191 | $66K | |
| 73562 | <1% | 786 | $64K | |
| 83690 | <1% | 5,185 | $64K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 577 | $61K |
| 96376 | <1% | 1,192 | $57K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,617 | $56K |
| 87581 | <1% | 1,673 | $56K | |
| 87486 | <1% | 1,673 | $55K | |
| 80305 | <1% | 2,682 | $54K | |
| 81001 | <1% | 8,621 | $51K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 117 | $48K |
| 84439 | <1% | 3,856 | $48K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,786 | $47K |
| 86140 | <1% | 5,153 | $45K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,731 | $43K |
| J3490 | Unclassified drugs | <1% | 6,238 | $43K |
| 72100 | <1% | 471 | $42K | |
| 64493 | <1% | 116 | $40K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 6,615 | $37K |
| 97161 | <1% | 1,160 | $35K | |
| 74022 | <1% | 398 | $34K | |
| 73030 | <1% | 421 | $34K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,146 | $32K |
| 83013 | <1% | 588 | $32K | |
| 73610 | <1% | 320 | $32K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 34 | $31K |
| 82553 | <1% | 2,308 | $30K | |
| 73630 | <1% | 459 | $30K | |
| 87071 | <1% | 1,623 | $30K | |
| 83874 | <1% | 2,187 | $29K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 179 | $29K |
| 83605 | <1% | 2,425 | $28K | |
| 87040 | <1% | 1,247 | $27K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 291 | $26K |
| 83735 | <1% | 3,824 | $25K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,865 | $25K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 391 | $22K |
| 85610 | <1% | 4,368 | $22K | |
| 82150 | <1% | 1,972 | $22K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 78 | $22K |
| 81025 | <1% | 1,994 | $22K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 251 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,722 | $21K |
| 80074 | <1% | 474 | $21K | |
| 73130 | <1% | 284 | $21K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,382 | $20K |
| 85730 | <1% | 3,058 | $20K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 528 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 608 | $20K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 610 | $20K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 113 | $17K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 87 | $17K |
| 85379 | <1% | 1,299 | $15K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 105 | $15K |
| 84403 | <1% | 623 | $15K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,566 | $15K |
| 64450 | <1% | 33 | $14K | |
| 84703 | <1% | 1,174 | $13K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 333 | $13K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 127 | $12K |
| 82607 | <1% | 739 | $11K | |
| 84481 | <1% | 587 | $10K | |
| 87186 | <1% | 932 | $10K | |
| 82043 | <1% | 1,164 | $10K | |
| 95992 | <1% | 436 | $10K | |
| 82670 | <1% | 348 | $10K | |
| 64494 | <1% | 76 | $10K | |
| 80320 | <1% | 614 | $9K | |
| 86703 | <1% | 614 | $9K | |
| 86235 | <1% | 72 | $9K | |
| 85652 | <1% | 1,343 | $8K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 16 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 213 | $7K |
| 83001 | <1% | 378 | $7K | |
| 86376 | <1% | 468 | $6K | |
| 62323 | <1% | 16 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,587 | $6K |
| 83525 | <1% | 415 | $6K | |
| 82728 | <1% | 394 | $6K | |
| 64495 | <1% | 44 | $5K | |
| 73110 | <1% | 85 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,327 | $5K |
| 73502 | <1% | 105 | $5K | |
| 82570 | <1% | 827 | $5K | |
| 76536 | <1% | 45 | $4K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,408 | $4K |
| 87428 | <1% | 61 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $4K |
| 88312 | <1% | 53 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 958 | $4K |
| 83540 | <1% | 524 | $4K | |
| 82550 | <1% | 532 | $4K | |
| 87807 | <1% | 148 | $4K | |
| 83550 | <1% | 374 | $4K | |
| 94762 | <1% | 65 | $4K | |
| 74178 | <1% | 15 | $4K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,779 | $4K |
| 87077 | <1% | 386 | $3K | |
| 74019 | <1% | 31 | $3K | |
| 86592 | <1% | 449 | $3K | |
| 87507 | <1% | 245 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,105 | $3K |
| 72110 | <1% | 28 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 954 | $2K |
| 86677 | <1% | 112 | $2K | |
| 82805 | <1% | 43 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 888 | $2K |
| 97032 | <1% | 115 | $2K | |
| 80329 | <1% | 113 | $1K | |
| 84153 | <1% | 87 | $1K | |
| 86000 | <1% | 37 | $1K | |
| 86780 | <1% | 91 | $1K | |
| 83014 | <1% | 116 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 414 | $1K |
| 80143 | <1% | 45 | $1K | |
| 84550 | <1% | 179 | $1K | |
| 80327 | <1% | 86 | $1K | |
| 86225 | <1% | 73 | $1K | |
| 86038 | <1% | 81 | $940.51 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 228 | $929.48 |
| 86431 | <1% | 119 | $892.29 | |
| 82948 | <1% | 139 | $871.71 | |
| 73080 | <1% | 12 | $752.11 | |
| 96367 | <1% | 13 | $667.99 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 26 | $652.64 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 421 | $604.92 |
| 84402 | <1% | 26 | $596.06 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 286 | $589.81 |
| 83655 | <1% | 39 | $579.22 | |
| 74018 | <1% | 14 | $576.77 | |
| 99001 | <1% | 123 | $537.45 | |
| 86200 | <1% | 38 | $510.89 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 197 | $508.06 |
| 84480 | <1% | 24 | $440.54 | |
| 84436 | <1% | 60 | $399.79 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 18 | $352.58 |
| 82274 | <1% | 24 | $344.52 | |
| 87338 | <1% | 25 | $329.26 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 129 | $297.20 |
| 82746 | <1% | 24 | $292.58 | |
| 90715 | <1% | 26 | $235.21 | |
| J1815 | Injection, insulin, per 5 units | <1% | 43 | $231.02 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 77 | $221.73 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 14 | $207.35 |
| 84100 | <1% | 38 | $194.89 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 65 | $194.82 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 33 | $190.77 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 33 | $169.78 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 124 | $169.37 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 78 | $162.87 |
| 87210 | <1% | 24 | $160.38 | |
| 77003 | <1% | 266 | $160.22 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 44 | $155.46 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 42 | $141.15 |
| A9270 | Non-covered item or service | <1% | 140 | $130.15 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 49 | $128.87 |
| 86706 | <1% | 13 | $120.61 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 90 | $117.25 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 25 | $103.38 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 32 | $89.18 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 68 | $50.92 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 33 | $42.29 |
| A4331 | Extension drainage tubing, any type, any length, with connector/adaptor, for use with urinary leg bag or urostomy pouch, each | <1% | 14 | $40.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 21 | $35.85 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 14 | $35.84 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 86 | $30.28 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 27 | $30.18 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 23 | $21.79 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 104 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOYER, WILLIAM (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Roosevelt County Special Hospital District | Clovis, NM | $3.41M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.